313 related articles for article (PubMed ID: 27899158)
1. High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy.
Falchi L; Sawas A; Deng C; Amengual JE; Colbourn DS; Lichtenstein EA; Khan KA; Schwartz LH; O'Connor OA
J Hematol Oncol; 2016 Nov; 9(1):132. PubMed ID: 27899158
[TBL] [Abstract][Full Text] [Related]
2. FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma.
Kasamon YL; de Claro RA; Wang Y; Shen YL; Farrell AT; Pazdur R
Oncologist; 2017 May; 22(5):585-591. PubMed ID: 28438889
[TBL] [Abstract][Full Text] [Related]
3. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation.
Armand P; Chen YB; Redd RA; Joyce RM; Bsat J; Jeter E; Merryman RW; Coleman KC; Dahi PB; Nieto Y; LaCasce AS; Fisher DC; Ng SY; Odejide OO; Freedman AS; Kim AI; Crombie JL; Jacobson CA; Jacobsen ED; Wong JL; Patel SS; Ritz J; Rodig SJ; Shipp MA; Herrera AF
Blood; 2019 Jul; 134(1):22-29. PubMed ID: 30952672
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
Armand P; Engert A; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman JM; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Shipp MA; Kato K; Sumbul A; Farsaci B; Ansell SM
J Clin Oncol; 2018 May; 36(14):1428-1439. PubMed ID: 29584546
[TBL] [Abstract][Full Text] [Related]
5. Low-dose pembrolizumab for relapsed/refractory Hodgkin lymphoma: high efficacy with minimal toxicity.
Chan TS; Luk TH; Lau JS; Khong PL; Kwong YL
Ann Hematol; 2017 Apr; 96(4):647-651. PubMed ID: 28138786
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitors in combination with radiotherapy as salvage treatment for relapsed/refractory classical Hodgkin lymphoma: A retrospective analysis in 12 patients.
Lucchini E; Rusconi C; Levis M; Ricci F; Santoro A; Ricardi U; Volpetti S; Matrone F; di Russo A; Caizzi M; Schiattarella A; Zaja F
Hematol Rep; 2021 Jun; 13(2):9080. PubMed ID: 34221295
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087.
Chen R; Zinzani PL; Lee HJ; Armand P; Johnson NA; Brice P; Radford J; Ribrag V; Molin D; Vassilakopoulos TP; Tomita A; von Tresckow B; Shipp MA; Lin J; Kim E; Nahar A; Balakumaran A; Moskowitz CH
Blood; 2019 Oct; 134(14):1144-1153. PubMed ID: 31409671
[TBL] [Abstract][Full Text] [Related]
8. Radiotherapy in combination with nivolumab for relapsed/refractory classical Hodgkin lymphoma: About two cases.
de Forceville L; Deau-Fischer B; Franchi P; Arsène-Henry A; Cassou Mounat T; Bouscary D; Kirova YM
Cancer Radiother; 2019 Jun; 23(3):232-239. PubMed ID: 31147173
[TBL] [Abstract][Full Text] [Related]
9. Clinical, Imaging Findings, Responses, and Outcomes of Patients With Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma Undergoing Immune Checkpoint Inhibitor Therapy: A Single-Institution Experience.
Liput J; Guler E; Smith DA; Tirumani SH; Hoimes C; Caimi PF; Ramaiya NH
J Comput Assist Tomogr; 2020; 44(4):619-626. PubMed ID: 32558769
[TBL] [Abstract][Full Text] [Related]
10. Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma.
Nie J; Wang C; Liu Y; Yang Q; Mei Q; Dong L; Li X; Liu J; Ku W; Zhang Y; Chen M; An X; Shi L; Brock MV; Bai J; Han W
J Clin Oncol; 2019 Jun; 37(17):1479-1489. PubMed ID: 31039052
[TBL] [Abstract][Full Text] [Related]
11. Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?
Khan N; Moskowitz AJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):227-233. PubMed ID: 28488185
[TBL] [Abstract][Full Text] [Related]
12. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma.
Armand P; Zinzani PL; Lee HJ; Johnson NA; Brice P; Radford J; Ribrag V; Molin D; Vassilakopoulos TP; Tomita A; von Tresckow B; Shipp MA; Herrera AF; Lin J; Kim E; Chakraborty S; Marinello P; Moskowitz CH
Blood; 2023 Sep; 142(10):878-886. PubMed ID: 37319435
[TBL] [Abstract][Full Text] [Related]
13. Long-term survival outcomes of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis.
Wang Z; Sun K; Zhu ZM; Zhang P; Yang J; Yang SW; Zheng MQ
Eur Rev Med Pharmacol Sci; 2021 Apr; 25(7):2941-2948. PubMed ID: 33877657
[TBL] [Abstract][Full Text] [Related]
14. Back to life with checkpoint inhibitors in Hodgkin lymphoma.
Dada R; Zekri J
J Oncol Pharm Pract; 2018 Mar; 24(2):139-142. PubMed ID: 28597713
[TBL] [Abstract][Full Text] [Related]
15. Low-dose pembrolizumab induced remission in patients with refractory classical Hodgkin lymphoma.
Kwong YL; Lopes D; Khong PL
Br J Haematol; 2017 Jan; 176(1):131-132. PubMed ID: 26773814
[No Abstract] [Full Text] [Related]
16. Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma.
LaCasce AS; Bociek RG; Sawas A; Caimi P; Agura E; Matous J; Ansell SM; Crosswell HE; Islas-Ohlmayer M; Behler C; Cheung E; Forero-Torres A; Vose J; O'Connor OA; Josephson N; Wang Y; Advani R
Br J Haematol; 2020 May; 189(3):e86-e90. PubMed ID: 32048731
[No Abstract] [Full Text] [Related]
17. Brentuximab vedotin as a salvage treatment for relapsed and refractory Hodgkin lymphoma patients in Taiwan.
Tien FM; Tsai CH; Liu JH; Lin CT
J Formos Med Assoc; 2019 Oct; 118(10):1466-1470. PubMed ID: 31337522
[TBL] [Abstract][Full Text] [Related]
18. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.
Bair SM; Strelec LE; Feldman TA; Ahmed G; Armand P; Shah NN; Singavi AN; Reddy N; Khan N; Andreadis C; Vu K; Huntington SF; Giri S; Ujjani C; Howlett C; Faheem M; Youngman MR; Nasta SD; Landsburg DJ; Schuster SJ; Svoboda J
Oncologist; 2019 Jul; 24(7):955-962. PubMed ID: 30568021
[TBL] [Abstract][Full Text] [Related]
19. Successful reversal of severe liver function impairment with Brentuximab vedotin in multiply relapsed/refractory classical Hodgkin lymphoma.
Spathas N; Belia M; Giannikos T; Arapaki M; Efstathopoulou M; Tsourouflis G; Gainaru G; Asimakopoulos J; Tsaftaridis P; K Angelopoulou M; Plata E; Konstantopoulos K; P Vassilakopoulos T
J BUON; 2019; 24(6):2483-2489. PubMed ID: 31983123
[TBL] [Abstract][Full Text] [Related]
20. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]